1. [1] M.E. Davis, Glioblastoma: Overview of disease and treatment, Clin J Oncol Nurs 20 (2016). https://doi.org/10.1188/16.CJON.S1.2-8 [DOI:10.1188/16.CJON.S1.2-8.]

2. [2] C. Boccellato, M. Rehm, Glioblastoma, from disease understanding towards optimal cell-based in vitro models, Cellular Oncology 45 (2022). https://doi.org/10.1007/s13402-022-00684-7 [DOI:10.1007/s13402-022-00684-7.]

3. [3] J. Li, L. Feng, Y. Lu, Glioblastoma multiforme: Diagnosis, treatment, and invasion, J Biomed Res 37 (2023). https://doi.org/10.7555/JBR.36.20220156 [DOI:10.7555/JBR.36.20220156.]

4. [4] W. Wu, J.L. Klockow, M. Zhang, F. Lafortune, E. Chang, L. Jin, Y. Wu, H.E. Daldrup-Link, Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance, Pharmacol Res 171 (2021). https://doi.org/10.1016/j.phrs.2021.105780 [DOI:10.1016/j.phrs.2021.105780.]

5. [5] S.S. Widodo, M. Dinevska, L.M. Furst, S.S. Stylli, T. Mantamadiotis, IL-10 in glioma, Br J Cancer 125 (2021). https://doi.org/10.1038/s41416-021-01515-6 [DOI:10.1038/s41416-021-01515-6.]

6. [6] B.T. Himes, P.A. Geiger, K. Ayasoufi, A.G. Bhargav, D.A. Brown, I.F. Parney, Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications, Front Oncol 11 (2021). https://doi.org/10.3389/fonc.2021.770561 [DOI:10.3389/fonc.2021.770561.]

7. [7] Y. Shiravand, F. Khodadadi, S.M.A. Kashani, S.R. Hosseini-Fard, S. Hosseini, H. Sadeghirad, R. Ladwa, K. O'byrne, A. Kulasinghe, Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology 29 (2022). https://doi.org/10.3390/curroncol29050247 [DOI:10.3390/curroncol29050247.]

8. [8] C. Robert, A decade of immune-checkpoint inhibitors in cancer therapy, Nat Commun 11 (2020). https://doi.org/10.1038/s41467-020-17670-y [DOI:10.1038/s41467-020-17670-y.]

9. [9] D. V. Chan, H.M. Gibson, B.M. Aufiero, A.J. Wilson, M.S. Hafner, Q.S. Mi, H.K. Wong, Differential CTLA-4 expression in human CD4+ versus CD8 + T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation, Genes Immun 15 (2014). https://doi.org/10.1038/gene.2013.57 [DOI:10.1038/gene.2013.57.]

10. [10] X. Zhang, L. Zhu, H. Zhang, S. Chen, Y. Xiao, CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges, Front Immunol 13 (2022). https://doi.org/10.3389/fimmu.2022.927153 [DOI:10.3389/fimmu.2022.927153.]

11. [11] N. Xie, G. Shen, W. Gao, Z. Huang, C. Huang, L. Fu, Neoantigens: promising targets for cancer therapy, Signal Transduct Target Ther 8 (2023). https://doi.org/10.1038/s41392-022-01270-x [DOI:10.1038/s41392-022-01270-x.]

12. [12] Z. Wang, Y.J. Cao, Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research, Front Immunol 11 (2020). https://doi.org/10.3389/fimmu.2020.00176 [DOI:10.3389/fimmu.2020.00176.]

13. [13] J.N. Sarkaria, L.S. Hu, I.F. Parney, D.H. Pafundi, D.H. Brinkmann, N.N. Laack, C. Giannini, T.C. Burns, S.H. Kizilbash, J.K. Laramy, K.R. Swanson, T.J. Kaufmann, P.D. Brown, N.Y.R. Agar, E. Galanis, J.C. Buckner, W.F. Elmquist, Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data, Neuro Oncol 20 (2018). https://doi.org/10.1093/neuonc/nox175 [DOI:10.1093/neuonc/nox175.]

14. [14] H. Luo, E. V. Shusta, Blood-brain barrier modulation to improve glioma drug delivery, Pharmaceutics 12 (2020). https://doi.org/10.3390/pharmaceutics12111085 [DOI:10.3390/pharmaceutics12111085.]

15. [15] X. Zhang, L. Zhao, H. Zhang, Y. Zhang, H. Ju, X. Wang, H. Ren, X. Zhu, Y. Dong, The immunosuppressive microenvironment and immunotherapy in human glioblastoma, Front Immunol 13 (2022). https://doi.org/10.3389/fimmu.2022.1003651 [DOI:10.3389/fimmu.2022.1003651.]

16. [16] L. van Hooren, S.M. Handgraaf, D.J. Kloosterman, E. Karimi, L.W.H.G. van Mil, A.A. Gassama, B.G. Solsona, M.H.P. de Groot, D. Brandsma, D.F. Quail, L.A. Walsh, G.R. Borst, L. Akkari, CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma, Nat Cancer 4 (2023). https://doi.org/10.1038/s43018-023-00547-6 [DOI:10.1038/s43018-023-00547-6.]

17. [17] A.D. Wong, M. Ye, A.F. Levy, J.D. Rothstein, D.E. Bergles, P.C. Searson, The blood-brain barrier: An engineering perspective, Front Neuroeng (2013). https://doi.org/10.3389/fneng.2013.00007 [DOI:10.3389/fneng.2013.00007.]

18. [18] W.M. Pardridge, The blood-brain barrier: Bottleneck in brain drug development, NeuroRx 2 (2005). https://doi.org/10.1602/neurorx.2.1.3 [DOI:10.1602/neurorx.2.1.3.]

19. [19] Y. Yang, Y. Cao, The impact of VEGF on cancer metastasis and systemic disease, Semin Cancer Biol 86 (2022). https://doi.org/10.1016/j.semcancer.2022.03.011 [DOI:10.1016/j.semcancer.2022.03.011.]

20. [20] P. Manders, L.V.A.M. Beex, V.C.G. Tjan-Heijnen, P.N. Span, C.G.J. Sweep, Vascular Endothelial Growth Factor is Associated with the Efficacy of Endocrine Therapy in Patients with Advanced Breast Carcinoma, Cancer 98 (2003). https://doi.org/10.1002/cncr.11764 [DOI:10.1002/cncr.11764.]

21. [21] R.S. D'Amico, M.K. Aghi, M.A. Vogelbaum, J.N. Bruce, Convection-enhanced drug delivery for glioblastoma: a review, J Neurooncol 151 (2021). https://doi.org/10.1007/s11060-020-03408-9 [DOI:10.1007/s11060-020-03408-9.]

22. [22] Y. Narita, T. Matsushima, Y. Sakamoto, H. Matsuoka, H. Tanioka, T. Kawakami, H. Shoji, T. Mizukami, N. Izawa, T. Nishina, Y. Yamamoto, S. Mitani, M. Nakamura, T. Misumi, K. Muro, Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study, ESMO Open 8 (2023). https://doi.org/10.1016/j.esmoop.2023.102071 [DOI:10.1016/j.esmoop.2023.102071.]

23. [23] B. Meléndez, C. Van Campenhout, S. Rorive, M. Remmelink, I. Salmon, N. D'Haene, Methods of measurement for tumor mutational burden in tumor tissue, Transl Lung Cancer Res 7 (2018). https://doi.org/10.21037/tlcr.2018.08.02 [DOI:10.21037/tlcr.2018.08.02.]

24. [24] D. Sha, Z. Jin, J. Budczies, K. Kluck, A. Stenzinger, F.A. Sinicrope, Tumor mutational burden as a predictive biomarker in solid tumors, Cancer Discov 10 (2020). https://doi.org/10.1158/2159-8290.CD-20-0522 [DOI:10.1158/2159-8290.CD-20-0522.]

25. [25] R. Büttner, J.W. Longshore, F. López-Ríos, S. Merkelbach-Bruse, N. Normanno, E. Rouleau, F. Penault-Llorca, Implementing TMB measurement in clinical practice: Considerations on assay requirements, ESMO Open 4 (2019). https://doi.org/10.1136/esmoopen-2018-000442 [DOI:10.1136/esmoopen-2018-000442.]

26. [26] D.A. Fruman, H. Chiu, B.D. Hopkins, S. Bagrodia, L.C. Cantley, R.T. Abraham, The PI3K Pathway in Human Disease, Cell 170 (2017). https://doi.org/10.1016/j.cell.2017.07.029 [DOI:10.1016/j.cell.2017.07.029.]

27. [27] Y. Zhang, B. Yan, Cell cycle regulation by carboxylated multiwalled carbon nanotubes through p53-independent induction of p21 under the control of the BMP signaling pathway, Chem Res Toxicol 25 (2012). https://doi.org/10.1021/tx300059m [DOI:10.1021/tx300059m.]

28. [28] A.B. Niculescu, X. Chen, M. Smeets, L. Hengst, C. Prives, S.I. Reed, Effects of p21 Cip1/Waf1 at Both the G 1 /S and the G 2 /M Cell Cycle Transitions: pRb Is a Critical Determinant in Blocking DNA Replication and in Preventing Endoreduplication , Mol Cell Biol 18 (1998). https://doi.org/10.1128/MCB.18.1.629 [DOI:10.1128/mcb.18.1.629.]

29. [29] K. Engeland, Cell cycle regulation: p53-p21-RB signaling, Cell Death Differ 29 (2022). https://doi.org/10.1038/s41418-022-00988-z [DOI:10.1038/s41418-022-00988-z.]

30. [30] L.C. Cantley, The phosphoinositide 3-kinase pathway, Science (1979) 296 (2002). https://doi.org/10.1126/science.296.5573.1655 [DOI:10.1126/science.296.5573.1655.]

31. [31] F. Xu, L. Na, Y. Li, L. Chen, Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours, Cell Biosci 10 (2020). https://doi.org/10.1186/s13578-020-00416-0 [DOI:10.1186/s13578-020-00416-0.]

32. [32] A. Gonzalez-Fierro, A. Dueñas-González, Drug repurposing for cancer therapy, easier said than done, Semin Cancer Biol 68 (2021). https://doi.org/10.1016/j.semcancer.2019.12.012 [DOI:10.1016/j.semcancer.2019.12.012.]

33. [33] C.K. Yaltirik, S.G. Yilmaz, S. Ozdogan, E.Y. Bilgin, Z. Barut, U. Ture, T. Isbir, Determination of IDH1, IDH2, MGMT, TERT and ATRX Gene Mutations in Glial Tumors, In Vivo (Brooklyn) 36 (2022). https://doi.org/10.21873/invivo.12881 [DOI:10.21873/invivo.12881.]

34. [34] A.M. Feyissa, G.A. Worrell, W.O. Tatum, K.L. Chaichana, M.E. Jentoft, H. Guerrero Cazares, N. Ertekin-Taner, S.S. Rosenfeld, K. ReFaey, A. Quinones-Hinojosa, Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control, Seizure 69 (2019). https://doi.org/10.1016/j.seizure.2019.05.018 [DOI:10.1016/j.seizure.2019.05.018.]

35. [35] R.S. Angom, N.M.R. Nakka, S. Bhattacharya, Advances in Glioblastoma Therapy: An Update on Current Approaches, Brain Sci 13 (2023). https://doi.org/10.3390/brainsci13111536 [DOI:10.3390/brainsci13111536.]

36. [36] L. Rong, N. Li, Z. Zhang, Emerging therapies for glioblastoma: current state and future directions, Journal of Experimental and Clinical Cancer Research 41 (2022). https://doi.org/10.1186/s13046-022-02349-7 [DOI:10.1186/s13046-022-02349-7.]

37. [37] M. Weller, M. van den Bent, M. Preusser, E. Le Rhun, J.C. Tonn, G. Minniti, M. Bendszus, C. Balana, O. Chinot, L. Dirven, P. French, M.E. Hegi, A.S. Jakola, M. Platten, P. Roth, R. Rudà, S. Short, M. Smits, M.J.B. Taphoorn, A. von Deimling, M. Westphal, R. Soffietti, G. Reifenberger, W. Wick, EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood, Nat Rev Clin Oncol 18 (2021). https://doi.org/10.1038/s41571-020-00447-z [DOI:10.1038/s41571-020-00447-z.]

38. [38] M. Ottenhausen, S.M. Krieg, B. Meyer, F. Ringel, Functional preoperative and intraoperative mapping and monitoring: Increasing safety and efficacy in glioma surgery, Neurosurg Focus 38 (2015). https://doi.org/10.3171/2014.10.FOCUS14611 [DOI:10.3171/2014.10.FOCUS14611.]

39. [39] F. Lang, B. Schrörs, M. Löwer, Ö. Türeci, U. Sahin, Identification of neoantigens for individualized therapeutic cancer vaccines, Nat Rev Drug Discov 21 (2022). https://doi.org/10.1038/s41573-021-00387-y [DOI:10.1038/s41573-021-00387-y.]

40. [40] B. Segura-Collar, S. Hiller-Vallina, O. de Dios, M. Caamaño-Moreno, L. Mondejar-Ruescas, J.M. Sepulveda-Sanchez, R. Gargini, Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators, Acta Neuropathol Commun 11 (2023). https://doi.org/10.1186/s40478-023-01569-y [DOI:10.1186/s40478-023-01569-y.]

41. [41] M. Das, X. Zhou, Y. Liu, A. Das, B.G. Vincent, J. Li, R. Liu, L. Huang, Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth, Transl Oncol 13 (2020). https://doi.org/10.1016/j.tranon.2020.100856 [DOI:10.1016/j.tranon.2020.100856.]

42. [42] C. Szeto, C.A. Lobos, A.T. Nguyen, S. Gras, TCR recognition of peptide-MHC-I: Rule makers and breakers, Int J Mol Sci 22 (2021). https://doi.org/10.3390/ijms22010068 [DOI:10.3390/ijms22010068.]

43. [43] A.K. Bentzen, S.R. Hadrup, T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation, Immuno-Oncology and Technology 2 (2019). https://doi.org/10.1016/j.iotech.2019.06.003 [DOI:10.1016/j.iotech.2019.06.003.]

44. [44] Q. He, X. Jiang, X. Zhou, J. Weng, Targeting cancers through TCR-peptide/MHC interactions, J Hematol Oncol 12 (2019). https://doi.org/10.1186/s13045-019-0812-8 [DOI:10.1186/s13045-019-0812-8.]

45. [45] B. Losic, A.J. Craig, C. Villacorta-Martin, S.N. Martins-Filho, N. Akers, X. Chen, M.E. Ahsen, J. von Felden, I. Labgaa, D. DʹAvola, K. Allette, S.A. Lira, G.C. Furtado, T. Garcia-Lezana, P. Restrepo, A. Stueck, S.C. Ward, M.I. Fiel, S.P. Hiotis, G. Gunasekaran, D. Sia, E.E. Schadt, R. Sebra, M. Schwartz, J.M. Llovet, S. Thung, G. Stolovitzky, A. Villanueva, Intratumoral heterogeneity and clonal evolution in liver cancer, Nat Commun 11 (2020). https://doi.org/10.1038/s41467-019-14050-z [DOI:10.1038/s41467-019-14050-z.]

46. [46] J.P. Ward, M.M. Gubin, R.D. Schreiber, The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer, in: Adv Immunol, 2016. https://doi.org/10.1016/bs.ai.2016.01.001 [DOI:10.1016/bs.ai.2016.01.001.]

47. [47] B.P. Babbitt, P.M. Allen, G. Matsueda, E. Haber, E.R. Unanue, Binding of immunogenic peptides to Ia histocompatibility molecules, Nature 317 (1985). https://doi.org/10.1038/317359a0 [DOI:10.1038/317359a0.]

48. [48] L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A.J.R. Aparicio, S. Behjati, A. V. Biankin, G.R. Bignell, N. Bolli, A. Borg, A.L. Børresen-Dale, S. Boyault, B. Burkhardt, A.P. Butler, C. Caldas, H.R. Davies, C. Desmedt, R. Eils, J.E. Eyfjörd, J.A. Foekens, M. Greaves, F. Hosoda, B. Hutter, T. Ilicic, S. Imbeaud, M. Imielinsk, N. Jäger, D.T.W. Jones, D. Jonas, S. Knappskog, M. Koo, S.R. Lakhani, C. López-Otín, S. Martin, N.C. Munshi, H. Nakamura, P.A. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J. V. Pearson, X.S. Puente, K. Raine, M. Ramakrishna, A.L. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T.N. Schumacher, P.N. Span, J.W. Teague, Y. Totoki, A.N.J. Tutt, R. Valdés-Mas, M.M. Van Buuren, L. Van 'T Veer, A. Vincent-Salomon, N. Waddell, L.R. Yates, J. Zucman-Rossi, P. Andrew Futreal, U. McDermott, P. Lichter, M. Meyerson, S.M. Grimmond, R. Siebert, E. Campo, T. Shibata, S.M. Pfister, P.J. Campbell, M.R. Stratton, Signatures of mutational processes in human cancer, Nature 500 (2013). https://doi.org/10.1038/nature12477 [DOI:10.1038/nature12477.]

49. [49] M. Yarchoan, B.A. Johnson, E.R. Lutz, D.A. Laheru, E.M. Jaffee, Targeting neoantigens to augment antitumour immunity, Nat Rev Cancer 17 (2017). https://doi.org/10.1038/nrc.2016.154 [DOI:10.1038/nrc.2016.154.]

50. [50] A. Halenius, C. Gerke, H. Hengel, Classical and non-classical MHC i molecule manipulation by human cytomegalovirus: So many targets - But how many arrows in the quiver?, Cell Mol Immunol 12 (2015). https://doi.org/10.1038/cmi.2014.105 [DOI:10.1038/cmi.2014.105.]

51. [51] K. Dhatchinamoorthy, J.D. Colbert, K.L. Rock, Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation, Front Immunol 12 (2021). https://doi.org/10.3389/fimmu.2021.636568 [DOI:10.3389/fimmu.2021.636568.]

52. [52] E.K. Bikoff, G. Kenty, L. Van Kaer, Distinct Peptide Loading Pathways for MHC Class II Molecules Associated with Alternative Ii Chain Isoforms, The Journal of Immunology 160 (1998). https://doi.org/10.4049/jimmunol.160.7.3101 [DOI:10.4049/jimmunol.160.7.3101.]

53. [53] M. Van Lith, R.M. McEwen-Smith, A.M. Benham, HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM, Journal of Biological Chemistry 285 (2010). https://doi.org/10.1074/jbc.M110.148155 [DOI:10.1074/jbc.M110.148155.]

54. [54] F.A. Castelli, C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, C. Nonn, H. Gahery-Ségard, J.-G. Guillet, A. Ménez, B. Georges, B. Maillère, HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity, The Journal of Immunology 169 (2002). https://doi.org/10.4049/jimmunol.169.12.6928 [DOI:10.4049/jimmunol.169.12.6928.]

55. [55] Y. Cai, R. Chen, S. Gao, W. Li, Y. Liu, G. Su, M. Song, M. Jiang, C. Jiang, X. Zhang, Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy, Front Oncol 12 (2023). https://doi.org/10.3389/fonc.2022.1054231 [DOI:10.3389/fonc.2022.1054231.]

56. [56] E. Karosiene, C. Lundegaard, O. Lund, M. Nielsen, NetMHCcons: A consensus method for the major histocompatibility complex class i predictions, Immunogenetics 64 (2012). https://doi.org/10.1007/s00251-011-0579-8 [DOI:10.1007/s00251-011-0579-8.]

57. [57] D.K. Wells, M.M. van Buuren, K.K. Dang, V.M. Hubbard-Lucey, K.C.F. Sheehan, K.M. Campbell, A. Lamb, J.P. Ward, J. Sidney, A.B. Blazquez, A.J. Rech, J.M. Zaretsky, B. Comin-Anduix, A.H.C. Ng, W. Chour, T. V. Yu, H. Rizvi, J.M. Chen, P. Manning, G.M. Steiner, X.C. Doan, A.A. Khan, A. Lugade, A.M.M. Lazic, A.A.E. Frentzen, A.D. Tadmor, A.S. Sasson, A.A. Rao, B. Pei, B. Schrörs, B. Berent-Maoz, B.M. Carreno, B. Song, B. Peters, B. Li, B.W. Higgs, B.J. Stevenson, C. Iseli, C.A. Miller, C.A. Morehouse, C.J.M. Melief, C. Puig-Saus, D. van Beek, D. Balli, D. Gfeller, D. Haussler, D. Jäger, E. Cortes, E. Esaulova, E. Sherafat, F. Arcila, G. Bartha, G. Liu, G. Coukos, G. Richard, H. Chang, H. Si, I. Zörnig, I. Xenarios, I. Mandoiu, I. Kooi, J.P. Conway, J.H. Kessler, J.A. Greenbaum, J.F. Perera, J. Harris, J. Hundal, J.M. Shelton, J. Wang, J. Wang, J. Greshock, J. Blake, J. Szustakowski, J. Kodysh, J. Forman, L. Wei, L.J. Lee, L.F. Fanchi, M. Slagter, M. Lang, M. Mueller, M. Lower, M. Vormehr, M.N. Artyomov, M. Kuziora, M. Princiotta, M. Bassani-Sternberg, M. Macabali, M.R. Kojicic, N. Yang, N.M.I. Raicevic, N. Guex, N. Robine, N. Halama, N.M. Skundric, O.S. Milicevic, P. Gellert, P. Jongeneel, P. Charoentong, P.K. Srivastava, P. Tanden, P. Shah, Q. Hu, R. Gupta, R. Chen, R. Petit, R. Ziman, R. Hilker, S.A. Shukla, S. Al Seesi, S.M. Boyle, S. Qiu, S. Sarkizova, S. Salama, S. Liu, S. Wu, S. Sridhar, S.L.C. Ketelaars, S. Jhunjhunwala, T. Shcheglova, T. Schuepbach, T.H. Creasy, V. Josipovic, V.B. Kovacevic, W. Fu, W.J. Krebber, Y.H. Hsu, Y. Sebastian, Z.K. Yalcin, Z. Huang, T. Merghoub, J. Guinney, A. Kolom, C. Selinsky, A. Ribas, M.D. Hellmann, N. Hacohen, A. Sette, J.R. Heath, N. Bhardwaj, F. Ramsdell, R.D. Schreiber, T.N. Schumacher, P. Kvistborg, N.A. Defranoux, Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction, Cell 183 (2020). https://doi.org/10.1016/j.cell.2020.09.015 [DOI:10.1016/j.cell.2020.09.015.]

58. [58] J.G. Abelin, D.B. Keskin, S. Sarkizova, C.R. Hartigan, W. Zhang, J. Sidney, J. Stevens, W. Lane, G.L. Zhang, T.M. Eisenhaure, K.R. Clauser, N. Hacohen, M.S. Rooney, S.A. Carr, C.J. Wu, Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction, Immunity 46 (2017). https://doi.org/10.1016/j.immuni.2017.02.007 [DOI:10.1016/j.immuni.2017.02.007.]

59. [59] X. Zhang, Y. Qi, Q. Zhang, W. Liu, Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy, Biomedicine and Pharmacotherapy 120 (2019). https://doi.org/10.1016/j.biopha.2019.109542 [DOI:10.1016/j.biopha.2019.109542.]

60. [60] S. Feola, J. Chiaro, B. Martins, V. Cerullo, Uncovering the tumor antigen landscape: What to know about the discovery process, Cancers (Basel) 12 (2020). https://doi.org/10.3390/cancers12061660 [DOI:10.3390/cancers12061660.]

61. [61] A.E. Zamora, J.C. Crawford, P.G. Thomas, Hitting the Target: How T Cells Detect and Eliminate Tumors, The Journal of Immunology 200 (2018). https://doi.org/10.4049/jimmunol.1701413 [DOI:10.4049/jimmunol.1701413.]

62. [62] S. Alrhmoun, S. Sennikov, The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions, Cancers (Basel) 14 (2022). https://doi.org/10.3390/cancers14246173 [DOI:10.3390/cancers14246173.]

63. [63] A. Apavaloaei, M.P. Hardy, P. Thibault, C. Perreault, The origin and immune recognition of tumor-specific antigens, Cancers (Basel) 12 (2020). https://doi.org/10.3390/cancers12092607 [DOI:10.3390/cancers12092607.]

64. [64] X.F. Li, P. Ren, W.Z. Shen, X. Jin, J. Zhang, The expression, modulation and use of cancer-testis antigens as potential biomarkers for cancer immunotherapy, Am J Transl Res 12 (2020).

65. [65] S.A. Wajed, P.W. Laird, T.R. DeMeester, DNA methylation: An alternative pathway to cancer, Ann Surg 234 (2001). https://doi.org/10.1097/00000658-200107000-00003 [DOI:10.1097/00000658-200107000-00003.]

66. [66] C. Liu, H. Tang, N. Hu, T. Li, Methylomics and cancer: the current state of methylation profiling and marker development for clinical care, Cancer Cell Int 23 (2023). https://doi.org/10.1186/s12935-023-03074-7 [DOI:10.1186/s12935-023-03074-7.]

67. [67] I. Meyts, B. Bosch, A. Bolze, B. Boisson, Y. Itan, A. Belkadi, V. Pedergnana, L. Moens, C. Picard, A. Cobat, X. Bossuyt, L. Abel, J.L. Casanova, Exome and genome sequencing for inborn errors of immunity, Journal of Allergy and Clinical Immunology 138 (2016). https://doi.org/10.1016/j.jaci.2016.08.003 [DOI:10.1016/j.jaci.2016.08.003.]

68. [68] S. Kumar, E.A. Gonzalez, P. Rameshwar, J.P. Etchegaray, Non-coding RNAs as mediators of epigenetic changes in malignancies, Cancers (Basel) 12 (2020). https://doi.org/10.3390/cancers12123657 [DOI:10.3390/cancers12123657.]

69. [69] Z. Zhang, M. Lu, Y. Qin, W. Gao, L. Tao, W. Su, J. Zhong, Neoantigen: A New Breakthrough in Tumor Immunotherapy, Front Immunol 12 (2021). https://doi.org/10.3389/fimmu.2021.672356 [DOI:10.3389/fimmu.2021.672356.]

70. [70] T. Jiang, T. Shi, H. Zhang, J. Hu, Y. Song, J. Wei, S. Ren, C. Zhou, Tumor neoantigens: From basic research to clinical applications, J Hematol Oncol 12 (2019). https://doi.org/10.1186/s13045-019-0787-5 [DOI:10.1186/s13045-019-0787-5.]

71. [71] J. Yu, Q. Wang, X. Zhang, Z. Guo, X. Cui, Mechanisms of Neoantigen-Targeted Induction of Pyroptosis and Ferroptosis: From Basic Research to Clinical Applications, Front Oncol 11 (2021). https://doi.org/10.3389/fonc.2021.685377 [DOI:10.3389/fonc.2021.685377.]

72. [72] T. Wongsurawat, P. Jenjaroenpun, V. Wanchai, I. Nookaew, Native RNA or cDNA Sequencing for Transcriptomic Analysis: A Case Study on Saccharomyces cerevisiae, Front Bioeng Biotechnol 10 (2022). https://doi.org/10.3389/fbioe.2022.842299 [DOI:10.3389/fbioe.2022.842299.]

73. [73] E.W. Hewitt, The MHC class I antigen presentation pathway: Strategies for viral immune evasion, Immunology 110 (2003). https://doi.org/10.1046/j.1365-2567.2003.01738.x [DOI:10.1046/j.1365-2567.2003.01738.x.]

74. [74] C. Lundegaard, O. Lund, M. Nielsen, Prediction of epitopes using neural network based methods, J Immunol Methods 374 (2011). https://doi.org/10.1016/j.jim.2010.10.011 [DOI:10.1016/j.jim.2010.10.011.]

75. [75] L. Peng, L. Zhou, H. Li, X. Zhang, S. Li, K. Wang, M. Yang, X. Ma, D. Zhang, S. Xiang, Y. Duan, T. Wang, C. Sun, C. Wang, D. Lu, M. Qian, Z. Wang, Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity, Cell Rep 43 (2024). https://doi.org/10.1016/j.celrep.2024.114003 [DOI:10.1016/j.celrep.2024.114003.]

76. [76] C.J. Liu, M. Schaettler, D.T. Blaha, J.A. Bowman-Kirigin, D.K. Kobayashi, A.J. Livingstone, D. Bender, C.A. Miller, D.M. Kranz, T.M. Johanns, G.P. Dunn, Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine, Neuro Oncol 22 (2020). https://doi.org/10.1093/neuonc/noaa050 [DOI:10.1093/neuonc/noaa050.]

77. [77] C.R.R. Barbosa, J. Barton, A.J. Shepherd, M. Mishto, Mechanistic diversity in MHC class I antigen recognition, Biochemical Journal 478 (2021). https://doi.org/10.1042/BCJ20200910 [DOI:10.1042/BCJ20200910.]

78. [78] N. Jiang, M. Malone, S. Chizari, Antigen-specific and cross-reactive T cells in protection and disease, Immunol Rev 316 (2023). https://doi.org/10.1111/imr.13217 [DOI:10.1111/imr.13217.]

79. [79] X. Zhao, X. Pan, Y. Wang, Y. Zhang, Targeting neoantigens for cancer immunotherapy, Biomark Res 9 (2021). https://doi.org/10.1186/s40364-021-00315-7 [DOI:10.1186/s40364-021-00315-7.]

80. [80] M. Peng, Y. Mo, Y. Wang, P. Wu, Y. Zhang, F. Xiong, C. Guo, X. Wu, Y. Li, X. Li, G. Li, W. Xiong, Z. Zeng, Neoantigen vaccine: An emerging tumor immunotherapy, Mol Cancer 18 (2019). https://doi.org/10.1186/s12943-019-1055-6 [DOI:10.1186/s12943-019-1055-6.]

81. [81] S.I. Hung, M.T. Chu, M.M. Hou, Y.S. Lee, C.K. Yang, S.Y. Chu, F.Y. Liu, H.C. Hsu, S.C. Pao, Y.C. Teng, C.B. Chen, A. Chao, W.H. Chung, J.W.C. Chang, C.H. Lai, Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer, Biomedicine and Pharmacotherapy 169 (2023). https://doi.org/10.1016/j.biopha.2023.115928 [DOI:10.1016/j.biopha.2023.115928.]

82. [82] Y. Zhu, Y. Qian, Z. Li, Y. Li, B. Li, Neoantigen-reactive T cell: An emerging role in adoptive cellular immunotherapy, MedComm (Beijing) 2 (2021). https://doi.org/10.1002/mco2.41 [DOI:10.1002/mco2.41.]

83. [83] F. Wei, X.X. Cheng, J.Z. Xue, S.A. Xue, Emerging Strategies in TCR-Engineered T Cells, Front Immunol 13 (2022). https://doi.org/10.3389/fimmu.2022.850358 [DOI:10.3389/fimmu.2022.850358.]

84. [84] F. Lu, X.J.N. Ma, W.L. Jin, Y. Luo, X. Li, Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges, Front Immunol 12 (2021). https://doi.org/10.3389/fimmu.2021.690565 [DOI:10.3389/fimmu.2021.690565.]

85. [85] J. Li, Z. Xiao, D. Wang, L. Jia, S. Nie, X. Zeng, W. Hu, The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells, Mol Cancer 22 (2023). https://doi.org/10.1186/s12943-023-01844-5 [DOI:10.1186/s12943-023-01844-5.]

86. [86] T. Wei, M. Leisegang, M. Xia, K. Kiyotani, N. Li, C. Zeng, C. Deng, J. Jiang, M. Harada, N. Agrawal, L. Li, H. Qi, Y. Nakamura, L. Ren, Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma, Oncoimmunology 10 (2021). https://doi.org/10.1080/2162402X.2021.1929726 [DOI:10.1080/2162402X.2021.1929726.]

87. [87] N. Hilf, S. Kuttruff-Coqui, K. Frenzel, V. Bukur, S. Stevanović, C. Gouttefangeas, M. Platten, G. Tabatabai, V. Dutoit, S.H. van der Burg, P. thor Straten, F. Martínez-Ricarte, B. Ponsati, H. Okada, U. Lassen, A. Admon, C.H. Ottensmeier, A. Ulges, S. Kreiter, A. von Deimling, M. Skardelly, D. Migliorini, J.R. Kroep, M. Idorn, J. Rodon, J. Piró, H.S. Poulsen, B. Shraibman, K. McCann, R. Mendrzyk, M. Löwer, M. Stieglbauer, C.M. Britten, D. Capper, M.J.P. Welters, J. Sahuquillo, K. Kiesel, E. Derhovanessian, E. Rusch, L. Bunse, C. Song, S. Heesch, C. Wagner, A. Kemmer-Brück, J. Ludwig, J.C. Castle, O. Schoor, A.D. Tadmor, E. Green, J. Fritsche, M. Meyer, N. Pawlowski, S. Dorner, F. Hoffgaard, B. Rössler, D. Maurer, T. Weinschenk, C. Reinhardt, C. Huber, H.G. Rammensee, H. Singh-Jasuja, U. Sahin, P.Y. Dietrich, W. Wick, Actively personalized vaccination trial for newly diagnosed glioblastoma, Nature 565 (2019). https://doi.org/10.1038/s41586-018-0810-y [DOI:10.1038/s41586-018-0810-y.]

88. [88] G. Forlani, J. Michaux, H.S. Pak, F. Huber, E.L. Marie Joseph, E. Ramia, B.J. Stevenson, M. Linnebacher, R.S. Accolla, M. Bassani-Sternberg, CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens, Molecular and Cellular Proteomics 20 (2021). https://doi.org/10.1074/mcp.RA120.002201 [DOI:10.1074/MCP.RA120.002201.]

89. [89] E.K. Winograd, M.J. Ciesielski, R.A. Fenstermaker, Novel vaccines for glioblastoma: Clinical update and perspective, Immunotherapy 8 (2016). https://doi.org/10.2217/imt-2016-0059 [DOI:10.2217/imt-2016-0059.]

90. [90] M.S. Ahluwalia, D.A. Reardon, A.P. Abad, W.T. Curry, E.T. Wong, S.A. Figel, L.L. Mechtler, D.M. Peereboom, A.D. Hutson, H.G. Withers, S. Liu, A.N. Belal, J. Qiu, K.M. Mogensen, S.S. Dharma, A. Dhawan, M.T. Birkemeier, D.M. Casucci, M.J. Ciesielski, R.A. Fenstermaker, Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma, Journal of Clinical Oncology 41 (2023). https://doi.org/10.1200/JCO.22.00996 [DOI:10.1200/JCO.22.00996.]

91. [91] D. Kreatsoulas, C. Bolyard, B.X. Wu, H. Cam, P. Giglio, Z. Li, Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence, J Hematol Oncol 15 (2022). https://doi.org/10.1186/s13045-022-01298-0 [DOI:10.1186/s13045-022-01298-0.]

92. [92] S. Izumoto, A. Tsuboi, Y. Oka, T. Suzuki, T. Hashiba, N. Kagawa, N. Hashimoto, M. Maruno, O.A. Elisseeva, T. Shirakata, M. Kawakami, Y. Oji, S. Nishida, S. Ohno, I. Kawase, J. Hatazawa, S.I. Nakatsuka, K. Aozasa, S. Morita, J. Sakamoto, H. Sugiyama, T. Yoshimine, Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme, J Neurosurg 108 (2008). https://doi.org/10.3171/JNS/2008/108/5/0963 [DOI:10.3171/JNS/2008/108/5/0963.]

93. [93] M. Khan, X. Li, M. Yan, Z. Li, H. Yang, G. Liao, Efficacy and safety of actively personalized neoantigen vaccination in the management of newly diagnosed glioblastoma: A systematic review, Int J Gen Med 14 (2021). https://doi.org/10.2147/IJGM.S323576 [DOI:10.2147/IJGM.S323576.]

94. [94] L. Bunse, T. Bunse, C. Krämer, Y.C. Chih, M. Platten, Clinical and Translational Advances in Glioma Immunotherapy, Neurotherapeutics 19 (2022). https://doi.org/10.1007/s13311-022-01313-9 [DOI:10.1007/s13311-022-01313-9.]

95. [95] E.J. Wherry, M. Kurachi, Molecular and cellular insights into T cell exhaustion, Nat Rev Immunol 15 (2015). https://doi.org/10.1038/nri3862 [DOI:10.1038/nri3862.]

96. [96] L. Buonaguro, M. Tagliamonte, Peptide-based vaccine for cancer therapies, Front Immunol 14 (2023). https://doi.org/10.3389/fimmu.2023.1210044 [DOI:10.3389/fimmu.2023.1210044.]

97. [97] B.A. Kansy, F. Concha-Benavente, R.M. Srivastava, H.B. Jie, G. Shayan, Y. Lei, J. Moskovitz, J. Moy, J. Li, S. Brandau, S. Lang, N.C. Schmitt, G.J. Freeman, W.E. Gooding, D.A. Clump, R.L. Ferris, PD-1 status in CD8+ T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer, Cancer Res 77 (2017). https://doi.org/10.1158/0008-5472.CAN-16-3167 [DOI:10.1158/0008-5472.CAN-16-3167.]

98. [98] T. Yang, Y. Shi, T. Liang, H. Xing, W. Ma, Y.M. Li, Y. Wang, Peptide vaccine against glioblastoma: from bench to bedside, Holistic Integrative Oncology 1 (2022). https://doi.org/10.1007/s44178-022-00021-w [DOI:10.1007/s44178-022-00021-w.]